Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK study of bezuclastinib + sunitinib versus sunitinib in gastrointestinal stromal tumors
NL-OMON59007Phase 3Active, not recruiting
- Sponsor
- Cogent Biosciences
- Start
- May 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bezuclastinib and sunitinib in gastrointestinal stromal tumor (GIST), sponsored by Cogent Biosciences. Primary endpoint: Progression-free survival. Started May 2023; status: active, not recruiting.
02
Drugs
bezuclastinibsunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON59007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59007.